Reven Holdings, Inc., a Delaware corporation, through its Golden, Colorado, based operating company Reven, LLC, is a biopharmaceutical company. Reven’s vision is to make a difference in the world by making its products accessible to everyone suffering the effects of vascular and metabolic related diseases. Reven is committed to being the premier, research-intensive biopharmaceutical company that advances the health and well-being of people around the world. Its primary product, Rejuveinix (RJX), targets patients suffering from COVID-19, sepsis, vascular and metabolic related diseases as well as specific patient populations suffering PAD and other cardiovascular related medical conditions.
Company: | Reven, LLC | |
Headquarters Address: | 600 Corporate Circle | |
Suite D | ||
Golden, CO 80401 | ||
Main Telephone: | (425) 305-9547 | |
Website: | ||
Type of Organization: | Private | |
Industry: | Biotechnology | |
Key Executives: | CEO: Peter Lange | |
COO: Brian Denomme | ||
CFO: Jeff Halverson | ||
Investor Relations | ||
Contact: | Jennifer Van Tuinen | |
Phone: | (720) 618-0658 | |
Email: | ||
Public Relations | ||
Contact: | Vincent Vanderbent | |
Phone: | (425) 305-9547 | |
Email: |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200710005003/en/